Wedbush Reaffirms Outperform Rating for Tango Therapeutics (TNGX)

Core Insights - Tango Therapeutics Inc. (NASDAQ:TNGX) is identified as one of the 10 most shorted biotech stocks to consider for investment by hedge funds [1] - Wedbush has raised the price target for Tango Therapeutics from $15 to $19, maintaining an Outperform rating, indicating a potential upside of over 12% [1] - Mizuho has also initiated coverage with an Outperform rating and a $19 price target, highlighting the potential of vopimetostat as a first-in-class and best-in-class therapy [4] Company Overview - Tango Therapeutics is a precision oncology company focused on developing targeted treatments for cancer patients with limited options [6] - The company's pipeline targets specific genetic vulnerabilities in tumors, with therapies in clinical trials aimed at challenging cancers such as pancreatic cancer, lung cancer, and glioblastoma [6] Product Development - Vopimetostat, a protein arginine methyltransferase 5 inhibitor, is on track to enter its first pivotal study in 2026, focusing on second-line pancreatic ductal adenocarcinoma [2] - Mizuho estimates that Tango could achieve $1.8 billion in risk-adjusted worldwide sales of vopimetostat by 2035, with positive Phase I data expected in 2026 [5]